SABRE CATALYSTS CONTAINING FLUORINATED CARBON CHAINS FOR DELIVERY OF METAL-FREE MRI CONTRAST AGENTS
China
202380043074.0
Filed on 2024-11-26
202380043074.0
Filed on 2024-11-26
CAR WITH DUAL-VARIABLE DOMAIN AND ENHANCED TCR-SIGNALING TARGETING CT-RCC-1 PEPTIDE AND METHODS OF USE
US Application 63/740,485
Filed on 2024-12-31
Filed on 2024-12-31
AZOLE COMPOUNDS USEFUL AS INHIBITORS OF VOLTAGE-DEPENDENT ANION CHANNEL OLIGOMERIZATION
US Application 63/663,336
Filed on 2024-06-24
Filed on 2024-06-24
SYSTEMS AND METHODS FOR INTRAMYOCARDIAL ABLATION
US Application 63/555,802
Filed on 2024-02-20
Filed on 2024-02-20
Prazoles as potential broad spectrum anti-viral agents
US Application 63/606,812
Filed on 2023-12-06
Filed on 2023-12-06
TISSUE CUTTING SYSTEMS AND METHODS
China
202180062140.X
Filed on 2023-03-10
202180062140.X
Filed on 2023-03-10
Devices And Methods For Cerclage Of Luminal Systems
China
202180049654.1
Filed on 2023-01-06
202180049654.1
Filed on 2023-01-06
Chemically Defined Culture Medium for Stem Cell Maintenance and Differentiation
European Patent
14781361.2
Filed on 2014-09-19
14781361.2
Filed on 2014-09-19
Sodium Nitrite as a Repurposed Pharmaceutical Agent Wins LES Deals of Distinction Award
The 2009 award winner for this category is a group of licensing agreements for the development of sodium nitrite as a repurposed pharmaceutical agent potentially effective against a number of serious medical conditions. The National Institutes of Health (NIH), supported by four university collaborators, was able complete exclusive license agreements with Hope Pharmaceuticals (for infused delivery) and Aires Pharmaceuticals (for inhaled delivery) to develop new treatments for conditions not well-managed by existing therapies.